Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Metastases in Genitourinary (Prostate, Bladder and Kidney) Cancers

Trial Profile

Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Metastases in Genitourinary (Prostate, Bladder and Kidney) Cancers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 May 2017

At a glance

  • Drugs Ferumoxytol (Primary)
  • Indications Bladder cancer; Prostate cancer; Renal cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 02 Mar 2017 Planned End Date changed from 30 Dec 2017 to 30 Dec 2018.
    • 02 Mar 2017 Planned primary completion date changed from 30 Dec 2017 to 6 Feb 2018.
    • 10 Feb 2017 Planned primary completion date changed from 6 Feb 2017 to 30 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top